CMAB vs IMAB in Metastatic Prostate Cancer

AstraZeneca15 enrolled

Overview

To evaluate the efficacy, safety and survival of two treatment regimens: Continuous Intermittent Maximum Androgen Blockade, using goserelin and bicalutamide in patients with prostate cancer. Primary endpoint is time to progression. Fifteen patients will be evaluated. QoL evaluation is also included.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Metastatic Prostate Cancer

Interventions

GoserelinDRUG

BicalutamideDRUG

Eligibility

Sex: MALEMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Histological diagnosis of D2 of Adenocarcinoma, * Naivety to treatment * Valuable bone metastasis Exclusion Criteria: * Hematological, liver or renal toxicity Grade IV * Severe and active infections

Locations (2)

Research Site

Metepec, Mexico

Research Site

Mexico City, Mexico

Outcomes

Primary Outcomes

Time to progression

Secondary Outcomes

Safety

Quality of Life

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.